Indian pharmaceutical intermediate and API manufacturer Hikal Limited (Hikal Limited) announced on June 19 that it has successfully developed Favipiravir API and its intermediates.
Fapiravir is a generic drug of Avigan, a drug of Toyama Chemical, a subsidiary of Fujifilm Corporation in Japan. The drug has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of new influenza virus infections. At present, in many countries, piravir is in different stages of clinical trials for the treatment of new coronavirus pneumonia.
It is reported that Hikal is negotiating with potential partners on the supply of the finished medicine.
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
The melamine market continues its upward trend and the price hits a new high!
The overall trend of the n-butanol market this month bottomed out and rebounded（202104）
Echemi Group ranked 71st in ICIS Top 100 Chemical Distributors in 2021
Asian May BDO contract prices fall from peak, spot market is expected to weaken
In 2027, the global flavor and fragrance market will reach $35.91 billion, with daily chemical flavors dominating
Add 600,000 tons of MDI production capacity! Wanhua Chemical’s global MDI production capacity will account for 32%!